How AI Simplifies Data Management for Drug Discovery

Get the Report

UTM Campaign:

UTM Medium:

UTM Source:

UTM Term:

Person Source:

Consent Source:

UTM Content:

ga.cid:

Egnyte_HP:

UTM_Egnyte_HP:

By registering I acknowledge I have read and understand Egnyte’s Privacy Policy and share your registration information with the event organizers and sponsors.

$985 million. That is the median cost of research and development of a new commercial drug.

This big business -- once a slow-paced, paper-first endeavor -- is now a promising new frontier for AI-driven innovation, helping to bring life-saving drugs to market faster.

It’s no small task. The estimated amount of health-care and life sciences data generated for each person in the world was 270GB as of 2020. That’s a huge volume of data to protect, keep compliant, and make sense of.

This report from MIT Technology Review Insights highlights how AI accelerates drug development by:

Managing vast troves of data from research and development through clinical trials
Protecting valuable IP and reducing regulatory burdens
Connecting globally distributed teams and trial sites
Streamline tasks such as tracking, auditing, and protecting personal health information